Molgramostim

Molgramostim is a human growth factor made by recombinant DNA technology with actions and uses similar to Filgrastim. It stimulates the production of white blood cells in bone marrow. Molgramostim is used to increase the white blood cell production in patient whose bone marrow function is depressed by cancer therapy. Molgramostim is also being used in the treatment of AIDS.

Brands
Adult Dose
Dose: 1 to 10 ug/kg
Single Dose: 5.5 (5.5)
Frequency: 24 hourly
Route: IV Inf
Instructions: -
Neonatal
Dose:
Single Dose:
Frequency:
Route:
Instructions: Not recommended in this age group
Paedriatic
Dose:
Single Dose:
Frequency:
Route:
Instructions: Not recommended in this age group
Characteristics
. It is of Semi Synthetic origin. It belongs to Granulocyte colony stimulating factor agonist pharmacological group on the basis of mechanism of action and also classified in Hematological Agents and Colony Stimulating Factor pharmacological group.
Contraindications
Molgramostim is contraindicated in conditions like Myeloid leukaemia.
Effects
Molgramostim produces potentially life-threatening effects which include Cardiac arrhythmias, Cardiac failure, Anaphylactic reactions. which are responsible for the discontinuation of Molgramostim therapy.The signs and symptoms that are produced after the acute overdosage of Molgramostim include Convulsions, Cerebrovascular disorders.The symptomatic adverse reactions produced by Molgramostim are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Fatigue, Nausea, Vomiting, Anorexia, Diarrhea, Dyspnea, Abdominal pain, Chills, Rashes, Confusion, Pruritus, SweatingX, Hypotension, Flushing, Asthenia, StomatitisX, Syncope, Chest pain, Rigors, Confusion, dizziness, Hypotension.
Indications
Molgramostim is primarily indicated in conditions like Acceleration of myeloid recovery following bone marrow transplantation, Adjunct in ganciclovir treatment, AIDS, Aplastic anemia, Bone marrow transplantation, Cytotoxic chemotherapy, Leucopaecia, Leukopenia, Myclodysplastic syndrome, Myelodysplastic syndrome, and can also be given in adjunctive therapy as an alternative drug of choice in Cancer.
Interactions
No data regarding the interactions of Molgramostim was found.
Interfrence
Risks
If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
Warnings
Caution in the patient with pre-existing pulmonary disease or a history of autoimmune disease. Regular monitoring of the white blood, differential blood counts, platelet count, hematocrit and serum albumin level is very important, safty in pregnancy is not established.
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.